HomeCompareCHJTF vs ABBV

CHJTF vs ABBV: Dividend Comparison 2026

CHJTF yields 3.02% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHJTF wins by $44.79M in total portfolio value· pulled ahead in Year 3
10 years
CHJTF
CHJTF
● Live price
3.02%
Share price
$1.02
Annual div
$0.03
5Y div CAGR
87.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.89M
Annual income
$39,983,177.94
Full CHJTF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CHJTF vs ABBV

📍 CHJTF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHJTFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHJTF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHJTF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHJTF
Annual income on $10K today (after 15% tax)
$256.35/yr
After 10yr DRIP, annual income (after tax)
$33,985,701.25/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CHJTF beats the other by $33,964,645.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHJTF + ABBV for your $10,000?

CHJTF: 50%ABBV: 50%
100% ABBV50/50100% CHJTF
Portfolio after 10yr
$22.50M
Annual income
$20,003,974.85/yr
Blended yield
88.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CHJTF
No analyst data
Altman Z
5.9
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHJTF buys
0
ABBV buys
0
No recent congressional trades found for CHJTF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHJTFABBV
Forward yield3.02%3.06%
Annual dividend / share$0.03$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR87.3%40.6%
Portfolio after 10y$44.89M$102.3K
Annual income after 10y$39,983,177.94$24,771.77
Total dividends collected$44.48M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHJTF vs ABBV ($10,000, DRIP)

YearCHJTF PortfolioCHJTF Income/yrABBV PortfolioABBV Income/yrGap
1$11,265$564.87$11,550$430.00$285.00ABBV
2$13,167$1,113.86$13,472$627.96$305.00ABBV
3← crossover$16,368$2,279.06$15,906$926.08+$462.00CHJTF
4$22,473$4,959.20$19,071$1,382.55+$3.4KCHJTF
5$35,965$11,918.72$23,302$2,095.81+$12.7KCHJTF
6$71,871$33,388.76$29,150$3,237.93+$42.7KCHJTF
7$193,699$116,796.73$37,536$5,121.41+$156.2KCHJTF
8$758,265$551,007.12$50,079$8,338.38+$708.2KCHJTF
9$4,587,110$3,775,766.40$69,753$14,065.80+$4.52MCHJTF
10$44,891,385$39,983,177.94$102,337$24,771.77+$44.79MCHJTF

CHJTF vs ABBV: Complete Analysis 2026

CHJTFStock

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Full CHJTF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CHJTF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHJTF vs SCHDCHJTF vs JEPICHJTF vs OCHJTF vs KOCHJTF vs MAINCHJTF vs JNJCHJTF vs MRKCHJTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.